Investment analysts at Leerink Swann initiated coverage on shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in a report released on Thursday. The firm set an “outperform” rating and a $175.00 price target on the stock. Leerink Swann’s target price suggests a potential upside of 15.70% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. Jefferies Group restated a “hold” rating on shares of Thermo Fisher Scientific in a research note on Thursday, August 4th. BTIG Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and set a $180.00 target price on the stock in a research note on Friday, July 22nd. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Mizuho set a $175.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, July 28th. Finally, Citigroup Inc. boosted their target price on shares of Thermo Fisher Scientific from $160.00 to $182.00 and gave the company a “buy” rating in a research note on Friday, July 29th. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $164.37.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific (NYSE:TMO) opened at 151.25 on Thursday. The stock’s 50 day moving average is $152.92 and its 200 day moving average is $151.85. The company has a market cap of $59.75 billion, a price-to-earnings ratio of 30.23 and a beta of 1.24. Thermo Fisher Scientific has a 52-week low of $119.75 and a 52-week high of $160.68.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, October 27th. The company reported $2.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.97 by $0.06. Thermo Fisher Scientific had a net margin of 11.10% and a return on equity of 14.95%. The firm had revenue of $4.49 billion for the quarter, compared to the consensus estimate of $4.39 billion. During the same quarter in the previous year, the company earned $1.80 earnings per share. The business’s revenue was up 8.9% compared to the same quarter last year. Equities research analysts forecast that Thermo Fisher Scientific will post $8.25 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, January 16th. Stockholders of record on Thursday, December 15th will be paid a $0.15 dividend. The ex-dividend date is Tuesday, December 13th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 12.00%.

In other news, SVP Daniel P. Shine sold 1,699 shares of the company’s stock in a transaction dated Monday, August 29th. The stock was sold at an average price of $152.28, for a total value of $258,723.72. Following the completion of the sale, the senior vice president now directly owns 17,437 shares of the company’s stock, valued at approximately $2,655,306.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 28,797 shares of the company’s stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $151.01, for a total value of $4,348,634.97. Following the completion of the sale, the chief executive officer now directly owns 307,444 shares of the company’s stock, valued at $46,427,118.44. The disclosure for this sale can be found here. 0.52% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in TMO. Bank of Montreal Can acquired a new position in shares of Thermo Fisher Scientific during the second quarter valued at about $32,053,000. Carmignac Gestion raised its position in shares of Thermo Fisher Scientific by 23.3% in the second quarter. Carmignac Gestion now owns 4,046,550 shares of the company’s stock valued at $597,918,000 after buying an additional 763,421 shares in the last quarter. Columbus Circle Investors raised its position in shares of Thermo Fisher Scientific by 363.2% in the second quarter. Columbus Circle Investors now owns 668,109 shares of the company’s stock valued at $98,720,000 after buying an additional 523,867 shares in the last quarter. First Pacific Advisors LLC raised its position in shares of Thermo Fisher Scientific by 5.9% in the second quarter. First Pacific Advisors LLC now owns 1,788,830 shares of the company’s stock valued at $264,318,000 after buying an additional 99,770 shares in the last quarter. Finally, Evercore Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 6.0% in the second quarter. Evercore Wealth Management LLC now owns 281,316 shares of the company’s stock valued at $41,568,000 after buying an additional 15,849 shares in the last quarter. 87.80% of the stock is owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Receive News & Stock Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related stocks with our FREE daily email newsletter.